Telesta Gets FDA Date, Stellar To Be Uplisted To NASDAQ, BMY Inks Deal

Telesta Therapeutics Inc’s (TST.TO) Biologics License Application for MCNA for non-muscle invasive bladder cancer has been accepted by the FDA for priority review, and the decision date has been set for February 27, 2016.